Investment Rating - The report assigns a "Buy" rating to the company, indicating that the stock price is expected to outperform the benchmark by more than 15% [14]. Core Views - The company has initiated a share buyback plan with a budget of up to HKD 100 million, reflecting confidence in its long-term growth and market performance [6][4]. - The board believes the current stock price does not reflect the company's true value and aims to enhance earnings per share (EPS) through share repurchases [4]. - The company is balancing short-term value realization with long-term strategic investments, including increased focus on smart supply chains and digital healthcare services [4]. Summary by Sections Company Performance and Market Position - The company has completed its warehousing and supply chain setup, with a cumulative registered buyer base of 827,000 by the end of 2024, including 491,000 pharmacies [5]. - The company is expected to achieve a compound annual growth rate (CAGR) of 145% in net profit from 2024 to 2027 [5]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are approximately HKD 20.81 billion, HKD 23.48 billion, and HKD 26.49 billion, with year-on-year growth rates of 16%, 13%, and 13% respectively [7]. - The net profit attributable to the parent company is projected to be HKD 1.29 billion, HKD 2.75 billion, and HKD 4.41 billion for the same years, reflecting significant growth rates of 331%, 112%, and 61% respectively [7]. Key Financial Metrics - The gross margin is expected to improve from 10.13% in 2024 to 11.49% in 2027 [6]. - The return on equity (ROE) is projected to increase from 1.29% in 2024 to 14.13% in 2027 [6]. - The price-to-earnings (P/E) ratio is expected to decrease from 104.90 in 2024 to 10.17 in 2027, indicating a more attractive valuation over time [6].